RJA
DNTH icon

Raymond James & Associates’s Dianthus Therapeutics DNTH Stock Holding History

Raymond James & Associates’s Portfolio DNTH Stock Details DNTH Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q3 		– Sell
-700
Closed -$110K – 4155
2021
Q2 		$110K Sell
700
-113
-14% -$20.8K ﹤0.01% 3824
2021
Q1 		$154K Buy
+813
New +$137K ﹤0.01% 3686

Other funds holding DNTH

TGI
TRV GP IV Boston, Massachusetts $254M AUM 426.76% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
GGHC
Gilder Gagnon Howe & Co New York $9.69B AUM 55.7% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $529M AUM 337.4% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return

Raymond James & Associates's DNTH Position: Q3 2021 in Review

Raymond James & Associates sold out of Dianthus Therapeutics (DNTH) in Q3 2021, closing a stake of 700 shares — an estimated $110K sold.

Raymond James & Associates first reported a position in DNTH in Q1 2021 and held it in 2 quarters. The position peaked at $154K in Q1 2021. 93 funds tracked by Wall St. Rank hold DNTH as of Q3 2021.

  • Raymond James & Associates reported no remaining Dianthus Therapeutics position as of Q3 2021 after selling out during the quarter.
  • Raymond James & Associates sold 700 Dianthus Therapeutics shares in Q3 2021, an estimated $110K.
  • Raymond James & Associates first reported a position in Dianthus Therapeutics in Q1 2021 and held it in 2 quarters.
  • Raymond James & Associates's Dianthus Therapeutics position peaked at $154K in Q1 2021.
  • 93 funds tracked by Wall St. Rank held Dianthus Therapeutics as of Q3 2021.

Based on Raymond James & Associates's 13F filing for Q3 2021, filed 2 Nov 2021.